Results 91 to 100 of about 28,958 (244)

Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands.

PLoS ONE, 2016
BackgroundDabigatran was proven to have similar effect on the prevention of recurrence of venous thromboembolism (VTE) and a lower risk of bleeding compared to vitamin K antagonists (VKA). The aim of this study is to assess the cost-effectiveness (CE) of
J Stevanović, L A de Jong, B S Kappelhoff, E P Dvortsin, M Voorhaar, M J Postma   +5 more
doaj   +1 more source

Factors affecting serum concentration of dabigatran in Asian patients with non-valvular atrial fibrillation

Journal of the Formosan Medical Association, 2019
Background/purpose: Dabigatran is effective in preventing ischemic stroke and systemic embolism in patients with atrial fibrillation. Although the therapeutic window for dabigatran is wide, its pharmacokinetic properties can differ between specific ...
Shin-Yi Lin, Sung-Chun Tang, Ching-Hua Kuo, Li-Kai Tsai, Shin-Joe Yeh, Li-Jiuan Shen, Jiann-Shing Jeng   +6 more
doaj   +1 more source

Oral Soft Tissue Biopsy in Patients Receiving Direct Oral Anticoagulants: A Prospective Cohort Study on Bleeding Outcomes

Oral Diseases, EarlyView.
ABSTRACT Background Direct oral anticoagulants (DOACs) are the first‐line therapy for stroke prevention in non‐valvular atrial fibrillation and venous thromboembolism. While evidence supports their continuation during routine dental procedures such as tooth extractions, data on oral soft tissue biopsies remain limited.
Rossana Izzetti, Chiara Cinquini, Antonio Barone, Marco Nisi   +3 more
wiley   +1 more source

UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays.

PLoS ONE, 2015
IntroductionThe fast, precise, and accurate measurement of the new generation of oral anticoagulants such as dabigatran and rivaroxaban in patients' plasma my provide important information in different clinical circumstances such as in the case of ...
Joachim Kuhn, Tatjana Gripp, Tobias Flieder, Marcus Dittrich, Doris Hendig, Jessica Busse, Cornelius Knabbe, Ingvild Birschmann   +7 more
doaj   +1 more source

Clinically Relevant Bleeding in Individuals With Cancer: Insights From a Nationwide Cohort Study

American Journal of Hematology, Volume 101, Issue 9, Page 2123-2136, September 2026.
ABSTRACT Cancer care is often complicated by coagulopathy leading to thrombosis and bleeding. While venous thromboembolism (VTE) has been extensively studied, bleeding remains an underestimated threat. To address this knowledge gap, we leveraged the Epic Cosmos database to determine the impact of cancer‐associated clinically relevant bleeding (CRB) in ...
Ming Y. Lim, Radhika Gangaraju, Omid Jafari, Zihan Yang, Joyce W. T. Tiong, Elizabeth C. L. Chiang, Shengling Ma, Jun Y. Jiang, Justine Ryu, Barbara D. Lam, Mrinal Ranjan, Ang Li   +11 more
wiley   +1 more source

Re-evaluating Safety and Effectiveness of Dabigatran Versus Warfarin in a Nationwide Data Environment: A Prevalent New-User Design Study

Drugs - Real World Outcomes, 2019
Introduction The new user cohort design is widely used to assess the effects of a new drug, such as dabigatran, but inherently excludes some users due to prior use of the comparator drug, for example warfarin.
Hui-Min Diana Lin, Chao-Lun Lai, Yaa-Hui Dong, Yu-Kang Tu, K. Arnold Chan, Samy Suissa   +5 more
doaj   +1 more source

FGL2‐HDAC11 Drives Immunothrombosis via NETs‐Mediated Endothelial Capillarization in MASLD Fibrosis

Advanced Science, Volume 13, Issue 44, 7 August 2026.
ABSTRACT Metabolic dysfunction–associated steatotic liver disease (MASLD) is frequently accompanied by hepatic fibrosis and systemic cardiovascular complications; however, the mechanistic interplay between coagulation abnormalities and disease progression remains poorly defined.
Xitang Li, Junjian Hu, Suping Hai, Peng Hu, Wenhui Wu, Qiang Gao, Binghui Yu, Feiyang Xu, Xizhe Zheng, Qianting Guan, Huiling Xiang, Dong Xi, Weiming Yan, Peng Wang, Bin‐hao Zhang, Qin Ning, Xiaojing Wang   +16 more
wiley   +1 more source

The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit–risk ratio

Therapeutic Advances in Neurological Disorders, 2015
Dabigatran is increasingly being used in clinical practice for the thromboprophylaxis in atrial fibrillation as a convenient therapy that needs no drug level monitoring. However, analysis of the data of the same clinical trial that led to the adoption of
Apostolos Safouris, Nikos Triantafyllou, John Parissis, Georgios Tsivgoulis   +3 more
doaj   +1 more source

Dabigatran for Mechanical Valves [PDF]

Hospital Pharmacy, 2014
Effective long-term oral anticoagulant therapy is required in patients who have received mechanical heart valves to reduce the risk of thromboembolism. Patients with mechanical heart valves are at high risk for cardioembolic stroke due to thrombus formation on the valve’s surface.
openaire   +2 more sources

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source